Forest Laboratories, Inc. Receives Subpoena on Benicar(R), Benicar HCT(R) and Azor(R)

Forest Laboratories, Inc. Receives Subpoena on Benicar(R), Benicar HCT(R) and Azor(R)


NEW YORK, May 09, 2011 (BUSINESS WIRE) --

Forest Laboratories, Inc. (NYSE:FRX) announced that it received a subpoena from the Office of the U.S. Attorney for the District of Massachusetts dated April 20, 2011. The subpoena requests documents relating to Benicar(R), Benicar HCT(R) (collectively "Benicar") and Azor(R), prescription medications approved for the treatment of hypertension. Forest co-marketed Benicar from 2002 to 2008 together with their originator Daiichi Sankyo, Inc. pursuant to co-promotion agreements. The Company intends to cooperate in responding to the subpoena.


About Forest Laboratories

Forest Laboratories' (NYSE:FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective and respiratory medicine. The Company's pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.

Benicar(R), Benicar HCT(R) and Azor(R) are registered trademarks of Daiichi Sankyo, Inc.


SOURCE: Forest Laboratories, Inc.

Forest Laboratories, Inc.Frank J. Murdolo, 212-224-6714Vice President - Investor [email protected]

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.